Cardiff Oncology Files 8-K on Shareholder Vote Matters
Ticker: CRDF · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1213037
| Field | Detail |
|---|---|
| Company | Cardiff Oncology, Inc. (CRDF) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, filing
TL;DR
Cardiff Oncology had a shareholder vote on June 20th, expect news on what they decided soon.
AI Summary
Cardiff Oncology, Inc. filed an 8-K on June 20, 2024, to report on matters submitted to a vote of its security holders. The filing indicates a shareholder meeting or vote took place on or around June 20, 2024, concerning corporate governance or strategic decisions.
Why It Matters
This filing signals that Cardiff Oncology has recently engaged its shareholders in a formal voting process, which could impact the company's future direction or governance.
Risk Assessment
Risk Level: low — The filing is procedural, reporting on a shareholder vote without disclosing specific outcomes or significant financial events.
Key Players & Entities
- Cardiff Oncology, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of Report
- 11055 Flintkote Avenue (address) — Principal Executive Offices
- San Diego, CA 92121 (address) — Principal Executive Offices
- Trovagene, Inc. (company) — Former Company Name
- XENOMICS INC (company) — Former Company Name
FAQ
What specific matters were submitted for a vote by Cardiff Oncology's security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not disclosed in this particular 8-K filing, which serves as a notification of the event.
When was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 20, 2024.
What is Cardiff Oncology's principal executive office address?
Cardiff Oncology's principal executive offices are located at 11055 Flintkote Avenue, San Diego, CA 92121.
Has Cardiff Oncology changed its name previously?
Yes, Cardiff Oncology, Inc. was formerly known as Trovagene, Inc. and prior to that, TrovaGene Inc. and XENOMICS INC.
What is the SIC code for Cardiff Oncology, Inc.?
The Standard Industrial Classification (SIC) code for Cardiff Oncology, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 691 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-20 16:03:29
Filing Documents
- crdf-20240620.htm (8-K) — 56KB
- crdf-20240620_g1.jpg (GRAPHIC) — 3KB
- 0001628280-24-029108.txt ( ) — 181KB
- crdf-20240620.xsd (EX-101.SCH) — 2KB
- crdf-20240620_lab.xml (EX-101.LAB) — 20KB
- crdf-20240620_pre.xml (EX-101.PRE) — 12KB
- crdf-20240620_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On June 20, 2024, Cardiff Oncology, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). A total of 27,736,982 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 25, 2024 are as follows: Proposal 1 . All of the seven (7) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the seven (7) directors was as follows: Directors For Against Abstain Broker Non Vote Mark Erlander, Ph.D. 15,221,656 0 601,956 11,913,370 Dr. Rodney Markin 15,518,934 0 304,679 11,913,369 Dr. James O. Armitage 15,435,187 0 388,426 11,913,369 Lale White 15,277,092 0 546,520 11,913,370 Gary W. Pace, Ph.D. 15,370,168 0 453,445 11,913,369 Mani Mohindru, Ph.D. 15,370,574 0 453,039 11,913,369 Renee P. Tannenbaum, Pharm.D. 15,213,729 0 609,883 11,913,370 Proposal 2. The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2024 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 27,146,093 264,563 326,325 1 Proposal 3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 8,150,000 shares was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 13,081,695 2,390,777 351,135 11,913,375 Proposal 4. The advisory vote on the compensation of the Company